NCT03322995View on ClinicalTrials.gov

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

First-line Chemotherapy

The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.

DRUG

Second-line Chemotherapy

Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.

RADIATION

Chemoradiation

50.4 Gy in 28 fractions.

Trial Locations (1)

53226

RECRUITING

Froedtert & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER